Dissolving microneedles to obtain rapid local anesthetic effect of lidocaine at skin tissue

Journal of Drug Targeting

Volumn 21, Issue 8, 2013, Pages 770-775

  Ito, Yukako ^a   Ohta, Junichi ^a   Imada, Kazuki ^a   Akamatsu, Shingo ^a   Tsuchida, Nozomi ^a   Inoue, Genta ^a   Inoue, Nana ^b   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b BioSerenTach Inc   (Japan)

Author keywords

Dissolving microneedles; Lidocaine; Percutaneous administration; Rat; Short onset time

Indexed keywords

CELLULOSE ACETATE; HYDROXYPROPYLCELLULOSE; LIDOCAINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREAM; DISSOLVING MICRONEEDLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; LOCAL ANESTHESIA; MALE; MICRONEEDLE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SKIN CULTURE; TISSUE BLOOD FLOW;

ABSORBABLE IMPLANTS; ANESTHETICS; ANESTHETICS, LOCAL; ANIMALS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; LIDOCAINE; MALE; NEEDLES; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION;

EID: 84883255840     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.811510     Document Type: Article

References (30)

1. Guy RH. Transdermal drug delivery. In: Schafer-Korting M, ed. Handbook of experimental pharmacology 197 drug delivery. Berlin: Springer; 2004: 399-410.
2. Barry B, Williams A. Penetration enhancers. Adv Drug Deliv Rev 2004;56: 603-18. (Pubitemid 38326936)
3. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004;56: 675-711. (Pubitemid 38326939)
4. Preat V, Vanbever R. Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev 2004;56: 659-74. (Pubitemid 38326938)
5. Doukas A. Transdermal delivery with a pressure wave. Adv Drug Deliv Rev 2004;56: 559-79.
6. Mitragotri S, Kost J. Low-frequency sonophoresis. Adv Drug Deliv Rev 2004;56: 589-601.
7. Wermeling DP, Banks SL, Hudson DA, et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci USA 2008;105: 2058-63. (Pubitemid 351439464)
8. Cormier M, Johnson B, Ameri M, et al. Transdermal delivery of desmopressin using a coated microneedle array patch system. J Control Release 2004;97: 503-11. (Pubitemid 38802952)
9. Prausnitz RM. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004;56: 581-7.
10. Levin G, Gershonowitz A, Sacks H, et al. Transdermal delivery of human growth hormone through RF-microchannels. Pharm Res 2005;22: 550-5. (Pubitemid 40603252)
11. Takada K. Microfabrication derived DDS: From batch to individual production. Drug Discov Ther 2008;2: 140-55.
12. Ito Y, Hagiwara E, Saeki A, et al. Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 2006;29: 82-8. (Pubitemid 44279397)
13. Ito Y, Yoshimitsu J, Shiroyama K, et al. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J Drug Target 2006;14: 255-62.
14. Ito Y, Murakami A, Maeda T, et al. Evaluation of self-dissolving needles containing low molecular weight heparin (LMWH) in rats. Int J Pharm 2008;349: 124-9. (Pubitemid 350299697)
15. Ito Y, Ohashi Y, Shiroyama K, et al. Self-dissolving micropiles for the percutaneous absorption of human growth hormone in rats. Biol Pharm Bull 2008;31: 1631-3.
16. Ito Y, Saeki A, Shiroyama K, et al. Percutaneous absorption of interferon-a by self-dissolving micropiles. J Drug Target 2008;16: 243-9. (Pubitemid 351460653)
17. Ito Y, Ohashi Y, Saeki A, et al. Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. Chem Pharm Bull 2008;56: 243-6. (Pubitemid 351463230)
18. Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol 2012;64: 1-29.
19. Coulman SA, Anstey A, Gateley C, et al. Microneedle mediated delivery of nanoparticles into human skin. Int J Pharm 2009;366: 190-200.
20. Kalluri H, Banga AK. Microneedles and transdermal drug delivery. J Drug Del Sci Tech 2009;19: 303-10.
21. Singh P, Roberts MS. Dermal and underlying tissue pharmacokinetics of lidocaine after topical application. J Pharm Sci 1994;83: 774-82. (Pubitemid 24233749)
22. Ito Y, Hamasaki N, Higashino H, et al. Method to increase the systemically delivered amount of drug from dissolving microneedles. Chem Pharm Bull 2013;61: 8-15.
23. Zhang Y, Siebenaler K, Brown K, et al. Adjuvants to prolong the local anesthetic effects of coated microneedle products. Int J Pharm 2012;439: 187-92.
24. Zhang Y, Brown K, Siebenaler K, et al. Development of lidocainecoated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm Res 2012;29: 170-7.
25. Morawski M, Alpár A, Bru?ckner G, et al. Chondroitin sulfate proteoglycan-based extracellular matrix in chicken (Gallus domesticus) brain. Brain Res 2009;1275: 10-23.
26. Faissner A, Clement A, Lochter A, et al. Isolation of a neural chondmitin sulfate proteoglycan with neurite outgrowth promoting properties. J Cell Biol 1994;126: 783-99. (Pubitemid 24241390)
27. Umehara Y, Yamada S, Nishimura S, et al. Chondroitin sulfate of appican, the proteoglycan form of amyloid precursor protein, produced by C6 glioma cells interacts with heparin-binding neuroregulatory factors. FEBS Lett 2004;557: 233-8. (Pubitemid 38115901)
28. Wilson TM, Snow DM. Chondroitin sulfate proteoglycan expression pattern in hippocampal development: potential regulation of axon tract formation. J Comp Neurol 2000; 424: 532-46. (Pubitemid 30670449)
29. Sintov A, Di-Capua N, Rubinstein A. Cross-linked chondroitin sulfate: characterization for drug delivery purposes. Biomaterials 1995;16: 473-8.
30. Tsai FM, Chiang LY, Wang FL, et al. Oral sustained delivery of diclofenac sodium using calcium chondroitin sulfate matrix. J Biomater Sci Polym Ed 2005;16: 1319-31.